


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	ALISKIREN FUMARATE
PRONUNCIATION	al is kye' ren fue' mar ate
THERAPEUTIC CLAIM	treatment of essential hypertension (renin inhibitor)

CHEMICAL NAMES

- 1) Benzeneoctanamide,  $\delta$ -amino-*N*-(3-amino-2,2-dimethyl-3-oxopropyl)- $\gamma$ -hydroxy-4-methoxy-3-(3-methoxypropoxy)- $\alpha,\zeta$ -bis(1-methylethyl)-, ( $\alpha S, \gamma S, \delta S, \zeta S$ )-, (*2E*)-2-butenedioate (2:1) (salt)
- 2) Bis(*2S,4S,5S,7S*)-5-amino-*N*-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide] (*2E*)-but-2-enedioate

STRUCTURAL FORMULA



MOLECULAR FORMULA	(C <sub>30</sub> H <sub>53</sub> N <sub>3</sub> O <sub>6</sub> ) <sub>2</sub> · C <sub>4</sub> H <sub>4</sub> O <sub>4</sub>
MOLECULAR WEIGHT	1219.6
TRADEMARK	Unknown as yet
MANUFACTURER	Novartis Pharma AG (Switzerland)
CODE DESIGNATION	SPP100
CAS REGISTRY NUMBER	173334-58-2

- NOTE: 1) This Statement of Adoption supersedes the Statement for aliskiren hemifumarate, adopted as USAN on March 30, 2005.  
 2) The USAN aliskiren hemifumarate is hereby rescinded.